References
- Dunn C J, Matheson A, Faulds D M. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19:135–161., [PUBMED], [INFOTRIEVE], [CSA]
- Michel M C, de la Rosette J J. Efficacy and safety of tamsulosin in the treatment of urologic diseases. Expert Opin Pharmacother 2004; 5:151–160., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chapple C R, Wyndaele J J, Nordling J, Boeminhaus F, Ypma A F, Abrams P. Tamsulosin the first prostate-selective-alpha 1A-adrenoreceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29:155–167., [PUBMED], [INFOTRIEVE], [CSA]
- Lijnen L PR, de Graff L. Systemic contact dermatitis from tamsulosin. Contact Dermatitis 2003; 49:50–51., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gokel Y, Dokur M, Paydas S. Doxazosine overdosage. Am J Emerg Med 2000; 18:638–639., [PUBMED], [INFOTRIEVE], [CSA]